1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
--------------------------
Date of Report (Date of earliest event reported):
NOVEMBER 21, 1996
CAMBRIDGE NEUROSCIENCE, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-19193 13-3319074
- --------------- ------------ -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
ONE KENDALL SQUARE, BUILDING 700, CAMBRIDGE, MA 02139
-----------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 225-0600
Total Number of Pages 6.
Exhibit Index at Page 4.
================================================================================
2
Item 5 - Other Events
- ---------------------
On November 21, 1996, Cambridge NeuroScience, Inc. (the "Company")
issued a news release announcing that it had entered into a collaboration with
Allergan Inc. to develop treatments for glaucoma and other ophthalmic diseases.
In conjunction with the signing of this collaboration agreement, on November 21
Allergan Inc. purchased 175,103 shares of Cambridge NeuroScience common stock
for $3.0 million, or $17.13 per share. The information contained in this news
release is incorporated herein by reference and filed as Exhibit 99.34 hereto.
Item 7 - Financial Statements and Exhibits
- ------------------------------------------
(c) Exhibits.
99.34 The Company's News Release dated November 21, 1996
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CAMBRIDGE NEUROSCIENCE, INC.
Date: November 21, 1996 /s/ Harry W. Wilcox, III
----------------------------------------
Harry W. Wilcox, III
Sr. Vice President, Finance and Business
Development; Chief Financial Officer
3
4
EXHIBIT INDEX
-------------
Exhibit
Sequential
Number Description Page
- ---------- ----------- ----
99.34 News Release dated November 21, 1996 5
4